Literature DB >> 6505693

Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens.

S Alexander, J H Elder.   

Abstract

Analysis of the ability of heteroantisera, monoclonal antibodies, and antibodies to synthetic peptides to react with viral glycoproteins deglycosylated with endoglycosidase F revealed that the reactivities of most of the antibodies to these glycoprotein antigens were influenced by the attached carbohydrate moieties. All heteroantisera prepared in rabbits or goats to either fully glycosylated retroviruses or influenza virus were virtually unreactive toward the viral glycoproteins after carbohydrate removal. Analyses with a panel of monoclonal antibodies to purified Rauscher murine leukemia virus gp70 indicated that the reactivity of most of these antibodies improved while the reactivity of others decreased or remain unchanged after carbohydrate removal. Most of the antibodies to synthetic peptide sequences in the influenza virus hemagglutinin also improved in reactivity after carbohydrate removal. These data indicate that carbohydrate side chains on viral glycoproteins influence the immune response to these antigens, and the more native the glycoprotein immunogen, the more dramatic the carbohydrate influence. Thus the immune response to these glycoproteins is not simply a function of the immunogenicity of certain domains over others but rather is a direct measure of carbohydrate influences on the host's perception of the foreign antigen.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6505693     DOI: 10.1126/science.6505693

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  48 in total

1.  Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.

Authors:  R J Pither; C X Zhang; C Shiels; J Tarlton; S Finerty; A J Morgan
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1.

Authors:  W R Lee; W J Syu; B Du; M Matsuda; S Tan; A Wolf; M Essex; T H Lee
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

3.  Species specificity of macaque rhadinovirus glycoprotein B sequences.

Authors:  M R Auerbach; S C Czajak; W E Johnson; R C Desrosiers; L Alexander
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  O-linked glycosylation of retroviral envelope gene products.

Authors:  A Pinter; W J Honnen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

Review 5.  Carbohydrate analysis of glycoproteins. A review.

Authors:  K B Lee; D Loganathan; Z M Merchant; R J Linhardt
Journal:  Appl Biochem Biotechnol       Date:  1990-01       Impact factor: 2.926

6.  Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.

Authors:  J P Moore; Q J Sattentau; R Wyatt; J Sodroski
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

7.  Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

Authors:  L S Sawyer; M T Wrin; L Crawford-Miksza; B Potts; Y Wu; P A Weber; R D Alfonso; C V Hanson
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Inhibition of type 5 adenovirus infectivity by periodate oxidation.

Authors:  G Ogier; Y Michal; V Thomas; G Quash; J D Rodwell
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

9.  Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques.

Authors:  J Overbaugh; L M Rudensey
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

10.  Human coronavirus NL63 open reading frame 3 encodes a virion-incorporated N-glycosylated membrane protein.

Authors:  Marcel A Müller; Lia van der Hoek; Daniel Voss; Oliver Bader; Dörte Lehmann; Axel R Schulz; Stephan Kallies; Tasnim Suliman; Burtram C Fielding; Christian Drosten; Matthias Niedrig
Journal:  Virol J       Date:  2010-01-15       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.